Business Profile & Competitive Position
Veeva Systems Inc. (VEEV) is classified in the Technology sector, Software - Application industry. The company delivers industry cloud solutions, data products, and business-consulting services purpose-built for the global life sciences industry. Its applications are organized around four major groups—Development Cloud, Quality Cloud, Commercial Cloud, and Data Cloud—and run primarily on the Veeva Vault platform. These tools help pharmaceutical and biotech customers manage drug development, regulatory compliance, quality systems, and commercialization workflows.
Scale is material: as of January 31, 2026, Veeva served 1,552 customers and employed 7,928 people worldwide, an increase of 637 employees from the prior year. Profitability metrics suggest the business has carved out a defensible niche. A net margin of 29.3% and return on equity of 14.0% are well above the averages for many application-software peers and indicate that the company can convert recurring revenue into earnings and shareholder returns. Those figures alone do not prove an unassailable moat, but they are consistent with a vertical SaaS model where deep life-sciences domain knowledge and integrated compliance workflows make switching costly.
Financial Posture
Veeva currently carries a market capitalization of $48.5 billion and trades at a P/E ratio of 48.2. That multiple reflects the premium typically assigned to profitable, subscription-based software companies, but it also means the stock is priced for continued execution. The 29.3% net margin and 14.0% ROE confirm the business is earning well on its capital base, while a beta of 0.88 implies the shares have historically been slightly less volatile than the broad equity market.
At the current snapshot, the stock is priced at $299.28, above the 50-day exponential moving average of $290.54, and the relative strength index sits at 46.3—near neutral territory. Those technical markers are descriptive rather than predictive, but they position the stock as neither overbought nor deeply oversold heading into the next earnings report.
Strategic Priorities & Outlook
Veeva's most recent 10-K outlines a clear ambition: to become the most strategic software, data, and business-consulting partner for drug development, quality and manufacturing, and commercialization across the life sciences industry. The company plans to deepen existing customer relationships through customer-success investments and targeted, industry-specific solutions rather than broad horizontal expansion.
Product investment is central. Veeva intends to spend on R&D to build new applications, expand functionality, and strengthen core technologies, while also growing its patent portfolio around Development Cloud, Commercial Cloud, Data Cloud, and Quality Cloud innovations. Operationally, Vault and certain Commercial Cloud applications run on Amazon Web Services, while Veeva CRM and related multichannel products currently use Salesforce hosting—a relationship that will continue to be supported until December 31, 2029. On the compliance side, the company holds ISO 9001 certification for its quality management system and maintains a data privacy program aligned with EU GDPR, UK GDPR, CCPA, and HIPAA.
Macro & Geopolitical Exposure
Because Veeva sits in the Software - Application industry and sells almost exclusively into life sciences, its macro exposure flows through the healthcare and pharmaceutical channel rather than through cyclical consumer demand. Revenue is tied to the R&D budgets, clinical-trial activity, regulatory burdens, and commercial spending of pharmaceutical and biotech firms. When drug-development pipelines expand, demand for development and quality clouds tends to improve; when biotech funding tightens or clinical trials slow, new subscription growth can soften.
Regulation is a double-edged theme. Stricter FDA, EMA, or other global health-agency requirements can increase demand for Veeva's compliance and quality tools, but they also raise the cost and complexity of maintaining approved software. Data privacy is especially relevant: multi-jurisdictional rules such as EU GDPR, UK GDPR, CCPA, and HIPAA create ongoing compliance obligations and potential liability if mishandled. International revenue also exposes the company to currency risk and data-sovereignty requirements in foreign markets, while trade policy can indirectly affect global pharmaceutical supply chains and customer spending.
Recent Developments
The most recent headline flow has centered on institutional positioning and the upcoming earnings calendar. On November 16, 2026, Seeking Alpha published the Thrivent Mid Cap Stock Fund Q3 2026 performance review and Defense World reported that Eurizon Capital SGR S.p.A. sold 5,541 shares of Veeva Systems. Two days earlier, on November 14, 2026, Defense World noted that Aberdeen Group plc purchased 1,904,153 shares—a substantially larger position change than the Eurizon sale. On November 12, 2026, Veeva announced via PR Newswire that it will release fiscal 2027 third quarter results after the market close on December 3, 2026.
The tone of the activity is mixed: one institutional buyer is accumulating while another is reducing, which is typical for a liquid, large-cap software name.
Earnings Behavior & Post-Earnings Drift
Veeva's earnings track record has been mechanically strong but not always rewarded by price. Over the last eight reported quarters, the company beat consensus EPS estimates in all eight periods, a 100% beat rate, with an average earnings surprise of 7.3%. Despite the beats, the average five-day price move following those reports was -1.42%, classified as a down drift.
The most recent quarter ended August 26, 2026, illustrates how a beat can still produce a sharp rally: actual EPS of $2.35 versus the $2.23 consensus (a 5.4% surprise) drove a 15.2% gain the next session and a 14.62% gain over the following five trading days. But the prior three prints show the opposite pattern. The June 3, 2026 quarter delivered EPS of $2.24 against a $2.14 estimate (4.7% surprise), yet the stock slipped 0.07% the next day and fell 8.37% over the following five days. The March 4, 2026 quarter posted $2.06 versus $1.94 (6.2% surprise), producing a 4.02% one-day pop but a -0.74% five-day drift. The November 20, 2025 quarter, with EPS of $2.04 versus $1.95 (4.6% surprise), saw the shares drop 9.77% the next day and 11.17% over the next five sessions.
That divergence suggests the market's real expectation may be running ahead of published consensus estimates. Beating the consensus has become the baseline, and the stock's direction after reports depends more on guidance, commentary, and incremental margins than on the beat itself. With fiscal Q3 2027 results due December 3, 2026 after the close, the current consensus EPS estimate is $2.34.
Frequently Asked Questions
What does Veeva Systems actually do?
Veeva is a provider of cloud software, data, and consulting services focused on the global life sciences industry. Its Development Cloud, Quality Cloud, Commercial Cloud, and Data Cloud applications help drug companies manage R&D, regulatory compliance, manufacturing quality, and product commercialization.
How has Veeva performed around earnings?
Over the last eight quarters, Veeva beat consensus EPS estimates every time, with an average surprise of 7.3%. However, the average five-day post-earnings price move was -1.42%, showing that beats do not always produce sustained rallies.
What should investors watch before the next earnings report?
Beyond the December 3, 2026 EPS consensus of $2.34, watchers should monitor guidance, customer-count trends, R&D commentary, and any updates on the Salesforce hosting arrangement through 2029 or broader life-sciences spending signals.
For a more comprehensive view of how institutional analysts are interpreting these figures, valuation, and upcoming catalysts, explore the full institutional verdict on Veeva Systems rather than relying on any single metric or recent headline.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-08-26 | $2.35 | $2.23 | +5.4% | +15.2% | +14.62% |
| 2026-06-03 | $2.24 | $2.14 | +4.7% | -0.07% | -8.37% |
| 2026-03-04 | $2.06 | $1.94 | +6.2% | +4.02% | -0.74% |
| 2025-11-20 | $2.04 | $1.95 | +4.6% | -9.77% | -11.17% |
| 2025-08-27 | $1.99 | $1.9 | +4.7% | - | - |
| 2025-05-28 | $1.97 | $1.74 | +13.2% | - | - |
Previous VEEV editions
Get the institutional verdict on VEEV
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the VEEV verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.